Logo

Devgen Awarded 1.9M Euro From Flemish Government

Nov 20, 2003

NEW YORK, Nov. 20 (GenomeWeb News) - Devgen has been awarded a grant for 1.9 million Euro ($2.3 million) from the Flemish Government in Flanders, Belgium to develop the company's C. elegans RNAi and genetics technology for identification of mechanism of action in human drugs, the company said today.

 

The Flemish Institute for the Promotion of Industrial Scientific and Technological Research has awarded the grant, the company said.

 

Devgen's technology uses RNAi to identify functionally validated genes in the model organism C. elegans. The company has in-house programs to develop therapies for metabolic and cardiovascular diseases, as well as development of nematode- and insect-resistant crops and novel pesticides.

Breaking News
The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.